| Completed |
: Therapy of Early Chronic Phase CML With Gleevec
: Leukemia, Myeloid, Chronic-Phase
: 2002-11-05
: Drug: Gleevec Starting dose of 400 mg orally daily.
|
| Completed |
: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
: Leukemia, Myeloid, Chronic-Phase
: 2016-03-16
: Drug: Pioglitazone PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased t
|
| Completed |
: Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
: Chronic Phase Chronic Myeloid Leukemia
: 2012-08-07
: Drug: Dasatinib tablets, oral, 100 mg, Once daily, Up to12 months on study,
|
| Active, not recruiting |
: Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
: Chronic Phase Chronic Myeloid Leukemia
: 2013-05-08
: Drug: Dasatinib Other Name: Sprycel
|
| Completed |
: Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
: Chronic Phase Chronic Myeloid Leukemia
: 2013-08-29
: Drug: P1101 Other Name: PEG-Proline-Interferon alpha-2b
|
| Not yet recruiting |
: Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
: Chronic Phase Chronic Myeloid Leukemia
: 2017-01-31
|
| Completed |
: Pioglityazone and Imatinib for CML Patients
: Leukemia, Myeloid, Chronic-Phase
: 2016-08-19
: Drug: Add-on therapy Pioglitazone therapy
|
| Active, not recruiting |
: Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
: Leukemia, Myeloid, Chronic-Phase
: 2013-05-14
: Drug: Nilotinib 300mg BID Nilotinib Other Name: Nilo
|
| Completed |
: Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response
: Leukemia, Myeloid, Chronic-Phase
: 2012-11-05
: Drug: Imatinib Mesylate Imatinib Mesylate LMC
|
| Completed |
: Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia
: Leukemia, Myeloid, Chronic-Phase
: 2012-11-08
: Drug: Dasatinib + PegIFN
|
